Loading...
Market
Caplyta receives additional FDA approval for new indication by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcements, press releases from Intra-Cellular Therapies or Johnson & Johnson
Story
Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6 Billion at $132 Per Share, Marking Largest Biotech Deal in Over a Year
Jan 13, 2025, 02:49 PM
Johnson & Johnson has agreed to acquire Intra-Cellular Therapies Inc. for approximately $14.6 billion, marking the largest biotech deal in over a year. The acquisition, announced at the J.P. Morgan Healthcare Conference, involves a purchase price of $132 per share. Intra-Cellular, co-founded by Sharon Mates in 2002, is known for its drug Caplyta, which received FDA approval in December 2019. The deal comes amidst a flurry of biotech acquisitions, with Eli Lilly and GSK also announcing significant purchases of Scorpion Therapeutics and IDRx, respectively, during the same conference.
View original story
Similar markets
None • 25%
Three or more • 25%
Two • 25%
One • 25%
Yes • 50%
No • 50%
Increases by more than 10% • 25%
Remains within 10% of current share • 25%
Other • 25%
Decreases by more than 10% • 25%
No • 50%
Yes • 50%
Not approved in USA or EU • 25%
Approved in both USA and EU • 25%
Approved in EU only • 25%
Approved in USA only • 25%
